Avalo Therapeutics
AVTX
97 hedge funds and large institutions have $464M invested in Avalo Therapeutics in 2026 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 30 increasing their positions, 20 reducing their positions, and 19 closing their positions.
654% more call options, than puts
Call options by funds: $43M | Put options by funds: $5.7M
275% more capital inflows, than outflows
Capital inflows: $250M | Capital outflows: $66.7M
74% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 19
50% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 20
15% more funds holding
Funds holding: 84 → 97 (+13)
125.66% less ownership
Funds ownership: 183.66% → 58% (-126%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$41.6M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$33.8M |
| 3 |
Avoro Capital Advisors
New York
|
+$22M |
| 4 |
Farallon Capital Management
San Francisco,
California
|
+$14.3M |
| 5 |
RTW Investments
New York
|
+$13.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
-$11.1M |
| 2 |
Silverarc Capital Management
Boston,
Massachusetts
|
-$9.5M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$5.92M |
| 4 |
Patient Square Capital
Menlo Park,
California
|
-$5.67M |
| 5 |
Jain Global
New York
|
-$3.95M |
AVTX Hedge Fund Activity: Q1 2026 in Review
97 of the 8,229 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q1 2026, worth a combined $464M — up 29% from $361M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new AVTX positions and 19 closed out — a net gain of 14 holders — while 30 added to existing stakes and 20 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $41.6M. The largest seller was OrbiMed, cutting an estimated $11.1M.
- 97 institutional investors held Avalo Therapeutics (AVTX) as of Q1 2026, up from 84 in Q4 2025.
- Funds reported $464M of Avalo Therapeutics stock for Q1 2026, up 29% quarter-over-quarter.
- 33 funds opened new Avalo Therapeutics positions in Q1 2026 and 19 closed out, a net change of +14 holders.
- The largest Avalo Therapeutics buyer in Q1 2026 was Fidelity Investments, an estimated $41.6M added.
- The largest Avalo Therapeutics seller in Q1 2026 was OrbiMed, an estimated $11.1M sold.
Based on aggregated 13F filings for Q1 2026.